NEO Looks 8.2% Overvalued on GF Value™

gurufocus.com · 2026-08-26

On August 26, 2026, NeoGenomics Inc (NASDAQ: NEO) announced a major expansion in Medicare coverage for its RaDaR ST molecular residual disease assay, now includ

TickrTrends take: NEO's valuation assessment indicates the stock may be trading above its estimated fair value by approximately 8 percent based on GF Value analysis. Given that TickrTrends is currently awaiting full valuation data on this healthcare company, investors focused on valuation metrics should monitor whether additional analysis will confirm or diverge from this overvaluation signal. The gap between current price and estimated value represents a metric that valuation-conscious investors typically track when evaluating entry and exit points in the healthcare sector.

Read the full story at gurufocus.com →